JPMorgan Downgrades Alnylam Pharmaceuticals (ALNY) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
FBR Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
August 10, 2015 5:42 PM EDTFBR Capital initiates coverage on Alnylam Pharmaceuticals (NASDAQ: ALNY) with a Outperform rating and a price target of $180.00.
Analyst Christopher S. James, M.D. commented, "Given its remarkably deep, diverse, and advanced pipeline, we view Alnylam as the best RNAi play in the... More
Alnylam Pharma (ALNY) Misses Q2 EPS by 10c
August 6, 2015 4:03 PM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($0.85), $0.10 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $8.69 million versus the consensus estimate of $12.64 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
... More